Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru

Descripción del Articulo

Ivermectin has emerged as a therapeutic option for various parasitic diseases, including strongyloidiasis, scabies, lice infestations, gnathostomiasis, and myiasis. This study comprehensively reviews the evidence-based indications for ivermectin in treating parasitic diseases, considering the unique...

Descripción completa

Detalles Bibliográficos
Autores: Failoc-Rojas, Virgilio E., Silva-Díaz, Heber, Maguiña, Jorge L., Rodriguez-Morales, Alfonso J., Díaz-Velez, Cristian, Apolaya-Segura, Moises, Valladares-Garrido, Mario J.
Formato: artículo
Fecha de Publicación:2023
Institución:Seguro Social de Salud
Repositorio:ESSALUD-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.essalud.gob.pe:20.500.12959/5158
Enlace del recurso:https://hdl.handle.net/20.500.12959/5158
https://doi.org/10.1016/j.parepi.2023.e00320
Nivel de acceso:acceso abierto
Materia:Ivermectin
Antiparasitic agents
Scientific evidence
Helminthiasis
Peru
https://purl.org/pe-repo/ocde/ford#3.01.09
id ESSA_59a9e7eac645545679d9cd614be5de41
oai_identifier_str oai:repositorio.essalud.gob.pe:20.500.12959/5158
network_acronym_str ESSA
network_name_str ESSALUD-Institucional
repository_id_str 4277
dc.title.es_PE.fl_str_mv Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru
title Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru
spellingShingle Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru
Failoc-Rojas, Virgilio E.
Ivermectin
Antiparasitic agents
Scientific evidence
Helminthiasis
Peru
https://purl.org/pe-repo/ocde/ford#3.01.09
title_short Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru
title_full Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru
title_fullStr Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru
title_full_unstemmed Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru
title_sort Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peru
author Failoc-Rojas, Virgilio E.
author_facet Failoc-Rojas, Virgilio E.
Silva-Díaz, Heber
Maguiña, Jorge L.
Rodriguez-Morales, Alfonso J.
Díaz-Velez, Cristian
Apolaya-Segura, Moises
Valladares-Garrido, Mario J.
author_role author
author2 Silva-Díaz, Heber
Maguiña, Jorge L.
Rodriguez-Morales, Alfonso J.
Díaz-Velez, Cristian
Apolaya-Segura, Moises
Valladares-Garrido, Mario J.
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Failoc-Rojas, Virgilio E.
Silva-Díaz, Heber
Maguiña, Jorge L.
Rodriguez-Morales, Alfonso J.
Díaz-Velez, Cristian
Apolaya-Segura, Moises
Valladares-Garrido, Mario J.
dc.subject.es_PE.fl_str_mv Ivermectin
Antiparasitic agents
Scientific evidence
Helminthiasis
Peru
topic Ivermectin
Antiparasitic agents
Scientific evidence
Helminthiasis
Peru
https://purl.org/pe-repo/ocde/ford#3.01.09
dc.subject.ocde.es_PE.fl_str_mv https://purl.org/pe-repo/ocde/ford#3.01.09
description Ivermectin has emerged as a therapeutic option for various parasitic diseases, including strongyloidiasis, scabies, lice infestations, gnathostomiasis, and myiasis. This study comprehensively reviews the evidence-based indications for ivermectin in treating parasitic diseases, considering the unique context and challenges in Peru. Fourteen studies were selected from a systematic search of scientific evidence on ivermectin in PubMed, from 2010 to July 2022. The optimal dosage of ivermectin for treating onchocerciasis, strongyloidiasis, and enterobiasis ranges from 150 to 200 μg/kg, while lymphatic filariasis requires a higher dose of 400 μg/kg (Brown et al., 2000). However, increased dosages have been associated with a higher incidence of ocular adverse events. Scientific evidence shows that ivermectin can be safely and effectively administered to children weighing less than 15 kg. Systematic reviews and meta-analyses provide strong support for the efficacy and safety of ivermectin in combating parasitic infections. Ivermectin has proven to be an effective treatment for various parasitic diseases, including intestinal parasites, ectoparasites, filariasis, and onchocerciasis. Dosages ranging from 200 μg/kg to 400 μg/kg are generally safe, with adjustments made according to the specific pathology, patient age, and weight/height. Given Peru's prevailing social and environmental conditions, the high burden of intestinal parasites and ectoparasites in the country underscores the importance of ivermectin in addressing these health challenges.
publishDate 2023
dc.date.accessioned.none.fl_str_mv 2024-10-01T14:55:20Z
dc.date.available.none.fl_str_mv 2024-10-01T14:55:20Z
dc.date.issued.fl_str_mv 2023-11-01
dc.type.es_PE.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.citation.es_PE.fl_str_mv Parasite Epidemiology and Control. 2023; 23.
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12959/5158
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.parepi.2023.e00320
identifier_str_mv Parasite Epidemiology and Control. 2023; 23.
url https://hdl.handle.net/20.500.12959/5158
https://doi.org/10.1016/j.parepi.2023.e00320
dc.language.iso.es_PE.fl_str_mv eng
language eng
dc.relation.uri.es_PE.fl_str_mv https://www.sciencedirect.com/science/article/pii/S2405673123000375
dc.rights.es_PE.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.es_PE.fl_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.es_PE.fl_str_mv application/pdf
dc.publisher.es_PE.fl_str_mv World Federation of Parasitologists
dc.source.none.fl_str_mv reponame:ESSALUD-Institucional
instname:Seguro Social de Salud
instacron:ESSALUD
instname_str Seguro Social de Salud
instacron_str ESSALUD
institution ESSALUD
reponame_str ESSALUD-Institucional
collection ESSALUD-Institucional
bitstream.url.fl_str_mv https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/1/Evidence-based%20indications%20for%20ivermectin%20in%20parasitic%20diseases.%20An%20integrated%20approach%20to%20context%20and%20challenges%20in%20Peru.pdf
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/2/license.txt
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/3/Evidence-based%20indications%20for%20ivermectin%20in%20parasitic%20diseases.%20An%20integrated%20approach%20to%20context%20and%20challenges%20in%20Peru.pdf.txt
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/4/Evidence-based%20indications%20for%20ivermectin%20in%20parasitic%20diseases.%20An%20integrated%20approach%20to%20context%20and%20challenges%20in%20Peru.pdf.jpg
bitstream.checksum.fl_str_mv ae2d4d40e5ef47d0b3820e482c4da980
8a4605be74aa9ea9d79846c1fba20a33
82f09acd329ee70a34687677cfa5a752
a03d86157b7a33d77ef0333a2f1e9c09
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Seguro Social de Salud – ESSALUD
repository.mail.fl_str_mv bibliotecacentral@essalud.gob.pe
_version_ 1813537115330314240
spelling Failoc-Rojas, Virgilio E.Silva-Díaz, HeberMaguiña, Jorge L.Rodriguez-Morales, Alfonso J.Díaz-Velez, CristianApolaya-Segura, MoisesValladares-Garrido, Mario J.2024-10-01T14:55:20Z2024-10-01T14:55:20Z2023-11-01Parasite Epidemiology and Control. 2023; 23.https://hdl.handle.net/20.500.12959/5158https://doi.org/10.1016/j.parepi.2023.e00320Ivermectin has emerged as a therapeutic option for various parasitic diseases, including strongyloidiasis, scabies, lice infestations, gnathostomiasis, and myiasis. This study comprehensively reviews the evidence-based indications for ivermectin in treating parasitic diseases, considering the unique context and challenges in Peru. Fourteen studies were selected from a systematic search of scientific evidence on ivermectin in PubMed, from 2010 to July 2022. The optimal dosage of ivermectin for treating onchocerciasis, strongyloidiasis, and enterobiasis ranges from 150 to 200 μg/kg, while lymphatic filariasis requires a higher dose of 400 μg/kg (Brown et al., 2000). However, increased dosages have been associated with a higher incidence of ocular adverse events. Scientific evidence shows that ivermectin can be safely and effectively administered to children weighing less than 15 kg. Systematic reviews and meta-analyses provide strong support for the efficacy and safety of ivermectin in combating parasitic infections. Ivermectin has proven to be an effective treatment for various parasitic diseases, including intestinal parasites, ectoparasites, filariasis, and onchocerciasis. Dosages ranging from 200 μg/kg to 400 μg/kg are generally safe, with adjustments made according to the specific pathology, patient age, and weight/height. Given Peru's prevailing social and environmental conditions, the high burden of intestinal parasites and ectoparasites in the country underscores the importance of ivermectin in addressing these health challenges.application/pdfengWorld Federation of Parasitologistshttps://www.sciencedirect.com/science/article/pii/S2405673123000375info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/IvermectinAntiparasitic agentsScientific evidenceHelminthiasisPeruhttps://purl.org/pe-repo/ocde/ford#3.01.09Evidence-based indications for ivermectin in parasitic diseases: An integrated approach to context and challenges in Peruinfo:eu-repo/semantics/articlereponame:ESSALUD-Institucionalinstname:Seguro Social de Saludinstacron:ESSALUDORIGINALEvidence-based indications for ivermectin in parasitic diseases. An integrated approach to context and challenges in Peru.pdfEvidence-based indications for ivermectin in parasitic diseases. An integrated approach to context and challenges in Peru.pdfapplication/pdf946264https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/1/Evidence-based%20indications%20for%20ivermectin%20in%20parasitic%20diseases.%20An%20integrated%20approach%20to%20context%20and%20challenges%20in%20Peru.pdfae2d4d40e5ef47d0b3820e482c4da980MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52TEXTEvidence-based indications for ivermectin in parasitic diseases. An integrated approach to context and challenges in Peru.pdf.txtEvidence-based indications for ivermectin in parasitic diseases. An integrated approach to context and challenges in Peru.pdf.txtExtracted texttext/plain36238https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/3/Evidence-based%20indications%20for%20ivermectin%20in%20parasitic%20diseases.%20An%20integrated%20approach%20to%20context%20and%20challenges%20in%20Peru.pdf.txt82f09acd329ee70a34687677cfa5a752MD53THUMBNAILEvidence-based indications for ivermectin in parasitic diseases. An integrated approach to context and challenges in Peru.pdf.jpgEvidence-based indications for ivermectin in parasitic diseases. An integrated approach to context and challenges in Peru.pdf.jpgGenerated Thumbnailimage/jpeg6750https://repositorio.essalud.gob.pe/bitstream/20.500.12959/5158/4/Evidence-based%20indications%20for%20ivermectin%20in%20parasitic%20diseases.%20An%20integrated%20approach%20to%20context%20and%20challenges%20in%20Peru.pdf.jpga03d86157b7a33d77ef0333a2f1e9c09MD5420.500.12959/5158oai:repositorio.essalud.gob.pe:20.500.12959/51582024-10-02 03:00:51.153Repositorio Seguro Social de Salud – ESSALUDbibliotecacentral@essalud.gob.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
score 13.888049
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).